BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33399078)

  • 21. Clinical Effect of CD25 on the Prognosis of Diffuse Large B Cell Lymphoma with Secondary Central Nervous System Relapse.
    Oka S; Ono K; Nohgawa M
    Pathol Oncol Res; 2020 Jul; 26(3):1843-1850. PubMed ID: 31768966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [CNS involvement and the feasibility of intratecal chemotherapy administration in patients with a nodal form of diffuse large B-cell lymphoma not otherwise specified. Data of prospective study].
    Magomedova AU; Misyurina AE; Mangasarova JK; Gorenkova LG; Margolin OV; Fastova EA; Kravchenko SK
    Ter Arkh; 2019 Jul; 91(7):35-40. PubMed ID: 32598734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular attributes underlying central nervous system and systemic relapse in diffuse large B-cell lymphoma.
    Isaev K; Ennishi D; Hilton L; Skinnider B; Mungall KL; Mungall AJ; Bakhtiari M; Tremblay-LeMay R; Silva A; Ben-Neriah S; Boyle M; Villa D; Marra MA; Steidl C; Gascoyne RD; Morin R; Savage KJ; Scott DW; Kridel R
    Haematologica; 2021 May; 106(5):1466-1471. PubMed ID: 32817292
    [No Abstract]   [Full Text] [Related]  

  • 24. Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals.
    Chang CC; Kampalath B; Schultz C; Bunyi-Teopengco E; Logan B; Eshoa C; Dincer AP; Perkins SL
    Arch Pathol Lab Med; 2003 Feb; 127(2):208-12. PubMed ID: 12562237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MYC/BCL2 Co-Expression Is a Stronger Prognostic Factor Compared With the Cell-of-Origin Classification in Primary CNS DLBCL.
    Shi QY; Feng X; Bao W; Ma J; Lv JH; Wang X; Rao Q; Shi QL
    J Neuropathol Exp Neurol; 2017 Nov; 76(11):942-948. PubMed ID: 29044419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
    Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
    Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
    [No Abstract]   [Full Text] [Related]  

  • 28. Common origin of sequential cutaneous CD30+ lymphoproliferations with nodal involvement evidenced by genome-wide clonal evolution.
    Xerri L; Adélaïde J; Avenin M; Guille A; Taix S; Bonnet N; Carbuccia N; Garnier S; Mescam L; Murati A; Chaffanet M; Coso D; Bouabdallah R; Bertucci F; Birnbaum D
    Histopathology; 2019 Mar; 74(4):654-662. PubMed ID: 30393995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis.
    Juskevicius D; Lorber T; Gsponer J; Perrina V; Ruiz C; Stenner-Liewen F; Dirnhofer S; Tzankov A
    Leukemia; 2016 Dec; 30(12):2385-2395. PubMed ID: 27198204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma of the CNS.
    Baraniskin A; Chomiak M; Ahle G; Gress T; Buchholz M; Turewicz M; Eisenacher M; Margold M; Schlegel U; Schmiegel W; Hahn S; Schroers R
    J Neurooncol; 2018 May; 137(3):463-468. PubMed ID: 29327175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary large B-cell lymphoma of the central nervous system with cyclin D1 expression and t(11;14) (IGH-CCND1): Diffuse large B-cell lymphoma with CCND1 rearrangement or mantle cell lymphoma?
    Parrott AM; Haggiagi AM; Murty VV; Bhagat G; Alobeid B
    Hematol Oncol; 2020 Dec; 38(5):817-822. PubMed ID: 32639587
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of Second Primary Lymphoma in Late Diffuse Large B-cell Lymphoma Recurrences.
    Berendsen MR; Bladel DAGV; Hesius E; de Groot FA; Kroeze LI; Rijntjes J; Luijks JACW; Hoevenaars B; Halilovic A; Nooijen P; Bladel EV; Jonge-Peeters S; Lensen C; Pruijt H; van der Spek E; Vermaat JSP; Hess C; Hebeda KM; Stevens WBC; van Krieken JHJM; van den Brand M; Groenen PJTA; Scheijen B
    Mod Pathol; 2023 May; 36(5):100119. PubMed ID: 36805792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis.
    King RL; Goodlad JR; Calaminici M; Dotlic S; Montes-Moreno S; Oschlies I; Ponzoni M; Traverse-Glehen A; Ott G; Ferry JA
    Virchows Arch; 2020 May; 476(5):647-665. PubMed ID: 31863183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma.
    Kansara R
    Curr Treat Options Oncol; 2018 Sep; 19(11):52. PubMed ID: 30203318
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary Intra-Axial Diffuse Large B-Cell Lymphoma in Immunocompetent Patients: Clinical Impact of Molecular Analysis and Histogenetic Evaluation.
    Cambruzzi E
    World Neurosurg; 2020 Feb; 134():215-220. PubMed ID: 31605845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas.
    Jiang Y; Redmond D; Nie K; Eng KW; Clozel T; Martin P; Tan LH; Melnick AM; Tam W; Elemento O
    Genome Biol; 2014 Aug; 15(8):432. PubMed ID: 25123191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma.
    Zheng M; Perry AM; Bierman P; Loberiza F; Nasr MR; Szwajcer D; Del Bigio MR; Smith LM; Zhang W; Greiner TC
    Neuropathology; 2017 Dec; 37(6):509-516. PubMed ID: 28856744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current strategies in the diagnosis of diffuse large B-cell lymphoma of the central nervous system.
    Baraniskin A; Deckert M; Schulte-Altedorneburg G; Schlegel U; Schroers R
    Br J Haematol; 2012 Feb; 156(4):421-32. PubMed ID: 22077417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MYC protein expression is associated with poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system.
    Tapia G; Baptista MJ; Muñoz-Marmol AM; Gaafar A; Puente-Pomposo M; Garcia O; Marginet-Flinch R; Sanz C; Navarro JT; Sancho JM; Ribera JM; Ariza A; Mate JL
    APMIS; 2015 Jul; 123(7):596-603. PubMed ID: 26010683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma.
    Mareschal S; Dubois S; Viailly PJ; Bertrand P; Bohers E; Maingonnat C; Jaïs JP; Tesson B; Ruminy P; Peyrouze P; Copie-Bergman C; Fest T; Jo Molina T; Haioun C; Salles G; Tilly H; Lecroq T; Leroy K; Jardin F
    Genes Chromosomes Cancer; 2016 Mar; 55(3):251-67. PubMed ID: 26608593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.